BioCentury
ARTICLE | Company News

Management tracks: Gilead, Ipsen, Depomed

October 18, 2017 10:55 PM UTC

Gilead Sciences Inc. (NASDAQ:GILD) promoted Alessandro Riva to EVP of oncology therapeutics. He was SVP of hematology and oncology therapeutic area head. Before joining Gilead this year, he was head of global oncology development at Novartis AG (NYSE:NVS; SIX:NOVN).

Cancer company Ipsen Group (Euronext:IPN; Pink:IPSEY) promoted Dominique Laymand to EVP, chief ethics and compliance officer from SVP, chief ethics and compliance officer...